{"id":"https://genegraph.clinicalgenome.org/r/8061f509-1dbc-4370-a56d-03a9e148243bv1.0","type":"EvidenceStrengthAssertion","dc:description":"The *GUCY2D* gene was first reported in relation to autosomal dominant cases of cone-rod dystrophy 6 (MONDO: 0011143) in 1998 (Kelsell et al., PMID: 9618177, Perrault et al. PMID: 9683616). Affected individuals have since been identified in a number of other publications (PMID: 10676808, PMID: 26298565, PMID: 25515582), with causal monoallelic variants in *GUCY2D*. Patients typically present with pediatric onset of progressively reduced visual acuity, myopia, photophobia, color vision defects, abnormalities of retinal pigmentation, and Bullâ€™s eye maculopathy. Electroretinogram readings indicate loss of cone responses and less severe loss of rod responses. Macular optical coherence tomography generally indicates reduced thickness of the retinal photoreceptor layers, which is accompanied by loss of cone cell density. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, these cases were compared with other diagnoses reported in association with *GUCY2D* variants. For example, cases from a large Northern Irish family linked to a monoallelic variant in *GUCY2D* have been diagnosed with central areolar choroidal dystrophy 1 (PMID: 22695961). While the associated variant is located outside of the dimerization domain, the shared mode of inheritance and phenotypic overlap led this disease entity to be combined with autosomal dominant cases of cone-rod dystrophy 6 into a single gene curation, with the lumped disease entity referred to as GUCY2D-related dominant retinopathy (MONDO:0100441). On the other hand, cases with overlapping phenotypes harboring biallelic *GUCY2D* variants have been diagnosed with autosomal recessive cone-rod dystrophy 6, Leber congenital amaurosis 1, or congenital stationary night blindness type 1I (PMID: 20517349). These cases differ in both their mode of inheritance and molecular mechanism (biallelic loss of function in the GUCY2D gene product). Therefore, recessive cases have been lumped into a separate disease entity, referred to as GUCY2D-related recessive retinopathy (MONDO: 0100453).\n\nNine suspected pathogenic variants have been scored as part of this curation (six missense variants disrupting codon 838, two additional missense variants disrupting the coiled-coil dimerization domain, and one variant in the C-terminal catalytic domain), which have been collectively reported in ten probands in six publications (PMID: 9618177, PMID: 9683616, PMID: 10676808, PMID: 26298565, PMID: 25515582, PMID: 22695961). All ten probands are heterozygous for their respective variants. One family with segregation evidence has contributed to the scoring of the gene-disease relationship (PMID: 9618177). More case-level data and families with segregation data are available in the above publications, but have not been scored as part of this curation as the maximum scoring for this evidence type has already been reached.\n\nThe mechanism of pathogenicity appears to be monoallelic *GUCY2D* dysfunction, characterized in most cases by missense variants in the region of *GUCY2D* encoding the dimerization-mediating coiled-coil domain. Nine out of ten probands found for this curation harbor a heterozygous variant allele within this region of *GUCY2D*. These substitutions are predicted to enhance the affinity of GUCY2D protein for its guanylate cyclase-activating protein GCAP-1 (GUCA1A), conferring the ability for the variant proteins to be enzymatically stimulated by GCAP-1 at higher concentrations of calcium ions than the wild-type protein (PMID: 10430891, PMID: 30319355). One of the autosomal dominant cases included in this curation harbors a heterozygous variant located outside of the dimerization-mediating domain, and will require additional functional study to confirm its mechanism of pathogenicity (PMID: 22695961).\n\nThis gene-disease association is supported by experimental evidence that *GUCY2D* expression is dramatically higher in the retina relative to control tissues (PMID: 30239781), particularly along the retinal outer nuclear layer (PMID: 1356371). Biochemical studies have demonstrated that *GUCY2D* encodes a receptor guanylyl cyclase that catalyzes cGMP production as part of the recovery of the dark state following visual excitation (PMID: 1356371). The enzymatic activity of GUCY2D protein is stimulated by the GCAP1 protein encoded by the *GUCA1A* gene, which harbors variants causal for autosomal dominant cone-rod dystrophy 3 (PMID: 10430891). Transgenic zebrafish (PMID: 23328348) and mouse models (PMID: 27703005) expressing a variant observed in affected human patients recapitulate features of the disease entity, including the mode of inheritance, electroretinogram abnormalities, retinal outer nuclear layer thinning, and photoreceptor cell loss.\n\nIn summary, *GUCY2D* is definitively associated with GUCY2D-related dominant retinopathy. This has been repeatedly demonstrated in both research and diagnostic settings, and has been upheld over time without the emergence of contradictory evidence, leading to a definitive classification. This classification was approved by the ClinGen Retinal GCEP on May 27, 2022 (SOP Version 8).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/8061f509-1dbc-4370-a56d-03a9e148243b","GCISnapshot":"https://genegraph.clinicalgenome.org/r/8816f73d-0432-4d50-bbb6-74a8f1da96ae","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/8816f73d-0432-4d50-bbb6-74a8f1da96ae_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10072","date":"2022-05-28T19:56:16.735Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/8816f73d-0432-4d50-bbb6-74a8f1da96ae_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10072","date":"2022-05-28T19:57:01.399Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8816f73d-0432-4d50-bbb6-74a8f1da96ae_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/933be791-bd77-4fc9-95b3-92cd0e8eabee","type":"EvidenceLine","dc:description":"NM_000180.4(GUCY2D):c.2521G>A (p.Glu841Lys) is a missense variant located within the coiled-coil domain that mediates dimerization. Codon 838 has proven to be a hot spot disrupted in other families similarly affected with autosomal dominant cone-rod dystrophy (PMID: 11115851, PMID: 12552567, PMID: 26298565). Cases from this family may be less severely affected, possibly similar to a reported variant at codon 849 (PMID: 26298565). The variant has been up-scored for its functional evidence and location near a known hot spot.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/933be791-bd77-4fc9-95b3-92cd0e8eabee_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"When heterologously expressed in HEK293 cells, this variant shows a reduction of baseline activity and a shift in sensitivity to GCAP1, the sensor protein that regulates its activity (PMID: 30319355, Figure 4B).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/933be791-bd77-4fc9-95b3-92cd0e8eabee_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25515582","allele":{"id":"https://genegraph.clinicalgenome.org/r/71734e08-120e-4be0-ac7e-b5c87a50c9af","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.2521G>A (p.Glu841Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/812328"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/2e642f3b-dcae-44ed-a5b1-c3493516971d","type":"EvidenceLine","dc:description":"The variant has been up-scored twice, due to functional evidence of impact on GUCY2D function and its location at a hot spot that is shared by multiple other variants observed in patients sharing the same diagnosis. It has not been up-scored further due to the lack of genome-wide genotyping for this patient.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e642f3b-dcae-44ed-a5b1-c3493516971d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000180.3(GUCY2D):c.[2511G>C;2512C>T;2516C>T] is a missense variant that causes three adjacent substitutions at the protein level (p.Glu837Asp;Arg838Cys;Thr839Met), located within the coiled-coil domain that mediates dimerization. Codon 838 has proven to be a hot spot disrupted in other families similarly affected with autosomal dominant cone-rod dystrophy (PMID: 9618177, PMID: 12552567, PMID: 26298565). The p.Arg838Cys substitution has been shown to disrupt the calcium sensitivity of GUCY2D and to trigger the inability to inactivate cyclase activity at high physiological calcium ion concentrations (PMID: 11115851).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2e642f3b-dcae-44ed-a5b1-c3493516971d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9683616","allele":{"id":"https://genegraph.clinicalgenome.org/r/cf1f92a7-b343-46b1-8ce7-eea2ff9387b9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.3(GUCY2D):c.[2511G>C;2512C>T;2516C>T]","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA226085"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/16f09051-294f-42a9-a7dd-498cc4b66068","type":"EvidenceLine","dc:description":"NM_000180.4(GUCY2D)):c.2545A>G (p.Thr849Ala) is a missense variant located within the coiled-coil domain that mediates dimerization. Missense variants at the nearby Codon 838 have proven to constitute a hot spot disrupted in other families similarly affected with autosomal dominant cone-rod dystrophy (PMID: 11115851, PMID: 12552567, PMID: 26298565). Cases from this family appear to be less severely affected than those associated with codon 838. The variant has been slightly up-scored due to its location near a known hot spot and the relatively thorough genotyping of the case.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/16f09051-294f-42a9-a7dd-498cc4b66068_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26298565","allele":{"id":"https://genegraph.clinicalgenome.org/r/29988e58-6762-4b39-b9f0-dcbf0b0b5a3f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.2545A>G (p.Thr849Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA397953755"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/55d86111-cbf6-48b4-9c5e-da89b42f9481","type":"EvidenceLine","dc:description":"NM_000180.4(GUCY2D):c.2798T>C (p.Val933Ala) is a missense variant located in exon 15, which is part of the catalytic domain rather than the coiled-coil domain that mediates dimerization. Other variants for this disease entity are located within the coiled-coil domain instead. It is not yet clear whether phenotypic differences between this case and those (later onset and absence of color vision defect, photophobia, and bull's eye maculopathy) reflect genotype-phenotype correlation or a distinct mechanism. Because of this ambiguity, this variant has not been scored.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/55d86111-cbf6-48b4-9c5e-da89b42f9481_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22695961","allele":{"id":"https://genegraph.clinicalgenome.org/r/a9c2e0b5-3c66-48eb-8ca4-8d2876e2a30f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.2798T>C (p.Val933Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/617917"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/02d065db-340e-4e9b-97ec-bf07016c29ea","type":"EvidenceLine","dc:description":"NM_000180.4(GUCY2D):c.2513G>C (p.Arg838Pro) is a missense variant located within the coiled-coil domain that mediates dimerization. Codon 838 has proven to be a hot spot disrupted in other families similarly affected with autosomal dominant cone-rod dystrophy (PMID: 11115851, PMID: 12552567, PMID: 26298565). The variant has been reported in an apparently unrelated family from this same publication.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/02d065db-340e-4e9b-97ec-bf07016c29ea_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26298565","allele":{"id":"https://genegraph.clinicalgenome.org/r/3e84400b-fb05-4ae2-a9bc-ced72ddc6253","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.2513G>C (p.Arg838Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/811743"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/598a9360-b9f6-482e-a263-f467f5975ce2","type":"EvidenceLine","dc:description":"NM_000180.4(GUCY2D):c.2513G>C (p.Arg838Pro) is a missense variant located within the coiled-coil domain that mediates dimerization. Codon 838 has proven to be a hot spot disrupted in other families similarly affected with autosomal dominant cone-rod dystrophy (PMID: 11115851, PMID: 12552567, PMID: 26298565). It has been up-scored for this location at a hot-spot as well as for its observation in an apparently unrelated (de novo) case from the same publication (PMID: 26298565).","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/598a9360-b9f6-482e-a263-f467f5975ce2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26298565","allele":{"id":"https://genegraph.clinicalgenome.org/r/3e84400b-fb05-4ae2-a9bc-ced72ddc6253"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/2774ad2f-9b4b-4fd3-acf5-323c441e25a2","type":"EvidenceLine","dc:description":"The variant has been up-scored twice, due to functional evidence of impact on GUCY2D function and its location at a hot spot that is shared by multiple other variants observed in patients sharing the same diagnosis. It has not been up-scored further due to the lack of genome-wide genotyping for this patient.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2774ad2f-9b4b-4fd3-acf5-323c441e25a2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000180.4(GUCY2D):c.2513G>A (p.Arg838His) is a missense variant located within the coiled-coil domain that mediates dimerization. Codon 838 has proven to be a hot spot disrupted in other families similarly affected with autosomal dominant cone-rod dystrophy (PMID: 11115851, PMID: 12552567, PMID: 26298565). The p.Arg838His substitution has been shown to disrupt the calcium sensitivity of GUCY2D and to trigger the inability to inactivate cyclase activity at high physiological calcium ion concentrations (PMID: 11115851).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2774ad2f-9b4b-4fd3-acf5-323c441e25a2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10676808","allele":{"id":"https://genegraph.clinicalgenome.org/r/f168f7d0-33ec-4da8-a7d5-825db51ecc25","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.2513G>A (p.Arg838His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA226086"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f1cfd20d-abb4-4b95-96c2-7caab6e6e438","type":"EvidenceLine","dc:description":"The variant has been up-scored for its location at a hot-spot for this disease entity, its recurrence in multiple probands including an apparent de novo case, and the functional evidence of its impact on gene function.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f1cfd20d-abb4-4b95-96c2-7caab6e6e438_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000180.4(GUCY2D):c.2513G>A (p.Arg838His) is a missense variant located within the coiled-coil domain that mediates dimerization. Codon 838 has proven to be a hot spot disrupted in other families similarly affected with autosomal dominant cone-rod dystrophy (PMID: 11115851, PMID: 12552567, PMID: 26298565). The variant has been reported in an apparently unrelated family from this same publication. The p.Arg838His substitution has been shown to disrupt the calcium sensitivity of GUCY2D and to trigger the inability to inactivate cyclase activity at high physiological calcium ion concentrations (PMID: 11115851).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/f1cfd20d-abb4-4b95-96c2-7caab6e6e438_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26298565","allele":{"id":"https://genegraph.clinicalgenome.org/r/f168f7d0-33ec-4da8-a7d5-825db51ecc25"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/40242651-0ddd-437b-9928-258605657244","type":"EvidenceLine","dc:description":"The evidence supporting the pathogenicity of the variant includes a transgenic mouse model that recapitulates the human patient phenotypes.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/40242651-0ddd-437b-9928-258605657244_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000180.3(GUCY2D):c.[2511G>C;2512C>A] is a missense variant that causes two adjacent substitutions at the protein level (p.Glu837Asp;Arg838Ser), located within the coiled-coil domain that mediates dimerization. Codon 838 has proven to be a hot spot disrupted in other families similarly affected with autosomal dominant cone-rod dystrophy (PMID: 11115851, PMID: 12552567, PMID: 26298565). The p.Arg838Ser substitution has also been shown to disrupt the calcium-dependent regulation of GUCY2D by GUCA1A (PMID: 15504042), decrease sensitivity to inhibition by RD3 (PMID: 27703005), and trigger blindness in a transgenic mouse model (PMID: 27703005).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/40242651-0ddd-437b-9928-258605657244_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9618177","allele":{"id":"https://genegraph.clinicalgenome.org/r/de8fb5f0-7a1b-454f-b0d9-de014d0ea728","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.3(GUCY2D):c.[2511G>C;2512C>A]","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA226082"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/8816f73d-0432-4d50-bbb6-74a8f1da96ae_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e792aa7e-3847-4576-ad5f-b02c3ebc8c66_proband_segregation","type":"FamilyCosegregation","dc:description":"The LOD score was published in a separate publication (PMID: 9097965) based on linkage mapping.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9618177","rdfs:label":"Kelsell_1998_CORD6_Family","estimatedLodScore":3.91,"family":{"id":"https://genegraph.clinicalgenome.org/r/e792aa7e-3847-4576-ad5f-b02c3ebc8c66","type":"Family","rdfs:label":"Kelsell_1998_CORD6_Family","member":{"id":"https://genegraph.clinicalgenome.org/r/4e451091-7cdd-404c-9fe8-89abde9e3768","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9618177","rdfs:label":"Kelsell_1998_CORD6_Family_Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":48,"allele":{"id":"https://genegraph.clinicalgenome.org/r/de8fb5f0-7a1b-454f-b0d9-de014d0ea728"},"detectionMethod":"The proband and his family members were subjected to sequencing of PCR products from each of the 18 exons of the GUCY2D locus. The PCR-amplified product from exon 13 was then subjected to HhaI restriction digest and resolved by agarose gel electrophoresis.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"While the proband is not described specifically, affected family members were generally described as exhibiting Peripheral visual field loss (HP:0007994), Photophobia (HP:0000613), Reduced visual acuity (HP:0007663), Undetectable light-adapted electroretinogram (HP:0030465), Cone/cone-rod dystrophy (HP:0000548), Bull's eye maculopathy (HP:0011504), Abnormal dark-adapted electroretinogram (HP:0030469).","phenotypes":"obo:HP_0007401","previousTesting":true,"previousTestingDescription":"In a previous publication (PMID: 9097965), the proband's family members were subjected to (genome-wide) linkage analysis mapping the affected phenotype to chromosome 17p12-p13. The LOD score associated with marker locus D17S1844 was 5.93 (with no recombination).","secondTestingMethod":"Restriction digest","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/40242651-0ddd-437b-9928-258605657244_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Central vision was lost before age 7, while peripheral field vision was lost by the fourth decade of life. Cone ERG was undetectable early on in the disease, while rod ERG abnormalities later developed progressively.","phenotypeNegativeAlleleNegative":19,"phenotypePositiveAllelePositive":14,"phenotypes":["obo:HP_0030465","obo:HP_0000613","obo:HP_0011504","obo:HP_0007663","obo:HP_0000548","obo:HP_0007994","obo:HP_0030469"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/4e451091-7cdd-404c-9fe8-89abde9e3768"},"publishedLodScore":5.93,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d20af84e-a570-4099-bdb5-2134eb8e29c3","type":"EvidenceLine","dc:description":"NM_000180.4(GUCY2D):c.2538G>C (p.Lys846Asn) is a missense variant located within the coiled-coil domain that mediates dimerization. Codon 838 has proven to be a hot spot disrupted in other families similarly affected with autosomal dominant cone-rod dystrophy (PMID: 11115851, PMID: 12552567, PMID: 26298565). Cases from this family may be less severely affected, possibly similar to a reported variant at codon 849 (PMID: 26298565). The variant has been up-scored for its functional evidence of gene impact and location near an established hot spot.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d20af84e-a570-4099-bdb5-2134eb8e29c3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"When heterologously expressed in HEK293 cells, this variant shows a reduction of baseline activity and a shift in sensitivity to GCAP1, the sensor protein that regulates its activity (PMID: 30319355, Figure 4B).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/d20af84e-a570-4099-bdb5-2134eb8e29c3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25515582","allele":{"id":"https://genegraph.clinicalgenome.org/r/282209af-6c17-4cae-ab20-37de557ee81f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.2538G>C (p.Lys846Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/812329"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":10.75},{"id":"https://genegraph.clinicalgenome.org/r/8816f73d-0432-4d50-bbb6-74a8f1da96ae_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8816f73d-0432-4d50-bbb6-74a8f1da96ae_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e5191c70-47ef-469b-a8a0-0b8dde7b61d8","type":"EvidenceLine","dc:description":"This transgenic model recapitulates the phenotypes of the human patients at the cellular level and within the electroretinogram data. Up-scoring has been performed to reflect the use of a transgene encoding a human patient variant, while down-scoring was performed to reflect the use of a rod-specific promoter that spares cones (critical to the human disease entity). The absence of additional visual phenotyping has also limited the evidence from being scored at a higher level of strength.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7f8c999e-e717-48e0-a743-b896fffcd4a8","type":"Finding","dc:description":"The model system approximately recapitulates the mode of inheritance (autosomal dominant) of the human disease state. At the molecular level, it increases the sensitivity of cGMP synthesis to calcium ion concentration (Figures 2B, 7A). At the ocular level, rod response (dark-adapted ERG) amplitudes were diminished starting at one month of age (Figure 4A, 4B), particularly by 6 months (Figure 5A, 5B), while cones lacking transgene expression remained functional (Figure 5A, 5C). Retinal morphology between 3 and 5 months of age showed outer nuclear layer reduction (Figures 6A, 7C) linked to photoreceptor loss (Figures 6B, 7D).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27703005","rdfs:label":"Transgenic mouse expressing human GUCY2D R838S","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/67478972-0542-4e10-9b54-2e3bcfff1fee","type":"EvidenceLine","dc:description":"The model recapitulates the mode of inheritance and the cellular / histological features of the human patients, but does not include characterized ocular phenotypes or ERG data. It has been up-scored due to the use of a variant from human patients.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d243fa48-46ab-42c2-809d-4bd5ac006116","type":"Finding","dc:description":"The model system approximately recapitulates the mode of inheritance (autosomal dominant) of the human disease state. Overexpression effects of the transgene were ruled out by comparison to the wild-type transgenic control, which did show some differences from the non-transgenic control. At the ocular level, larval optokinetic response (visual behavior) was normal (Figure 2A). At the cellular/microscopic level, cone morphology was disrupted (Figures 2, 3, 4) and cone density was reduced (Figure 2), along with the thickness of the (rod) outer nuclear layer (Figure 5).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23328348","rdfs:label":"Transgenic zebrafish expressing human GUCY2D R838S","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/8816f73d-0432-4d50-bbb6-74a8f1da96ae_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a7fbe383-e983-456e-97fc-0b7c1a11cf56","type":"EvidenceLine","dc:description":"The ability of GUCY2D to catalyze cGMP production is consistent with the loss of photoreceptor function in patients and the known association between abnormalities in cGMP levels and photoreceptor degeneration.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c9be79e5-3909-499b-9bc2-5374ec63cdb6","type":"Finding","dc:description":"The ability of the exogenously expressed enzyme to efficiently catalyze cGMP production is consistent with the loss of photoreceptor function that is characteristic of the disease, as abnormalities in cGMP levels have long been associated with photoreceptor degeneration (PMID: 4369896).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1356371","rdfs:label":"GUCY2D produces cGMP as a receptor guanylyl cyclase","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/da9291c1-0b64-4b16-a441-adaad0127d56","type":"EvidenceLine","dc:description":"The default score is appropriate, as the two interacting proteins are both encoded by genes reported to be causal in autosomal dominant cases of cone-rod dystrophy.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/049565ed-73ea-4705-ba04-f4fa2a35b018","type":"Finding","dc:description":"Interaction was established by enzymatic assay (Figure 3) showing that cGMP production by GUCY2D is specifically and dose-dependently stimulated in vitro by GUCA1A (known in the paper as GCAP-1) but not by GUCA1B (known in the paper as GCAP-2).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10430891","rdfs:label":"GUCY2D protein-protein interaction with GUCA1A","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c87c39ff-e08e-459a-815a-99b0be8ca6c6","type":"EvidenceLine","dc:description":"The high level of specificity of GUCY2D mRNA expression to the retina (at twice the level of the closest non-retinal tissue) has been used as a rationale to up-score this data from 0.5 to 1 point.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fbd695d7-9a18-42a2-aadc-5e55cff2b1c2","type":"Finding","dc:description":"Evidence from the Pan-Tissue Plots feature indicates that the expression of GUCY2D at the mRNA level is far higher in adult retina tissue than in any other tissue type with available RNA-seq data found in the database. GUCY2D expression in adult retina is approximately twice that of the second-highest tissue (testis). An alternative database lacking eye data (GTEx, PMID: 23715323) is compatible with this finding in that it shows GUCY2D levels peaking in the testis (https://gtexportal.org/home/gene/GTEX).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30239781","rdfs:label":"GUCY2D mRNA is highly expressed in human retina","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5}],"evidenceStrength":"Definitive","sequence":4509,"specifiedBy":"GeneValidityCriteria8","strengthScore":15.75,"subject":{"id":"https://genegraph.clinicalgenome.org/r/EMBL5GSafnU","type":"GeneValidityProposition","disease":"obo:MONDO_0100441","gene":"hgnc:4689","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_8816f73d-0432-4d50-bbb6-74a8f1da96ae-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}